Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuromuscular Junction Disorders and Congenital Myasthenic Syndrome Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAPSN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAPSN Recombinant Protein (Wild Type / N88K Mutant) High purity (>95%), Endotoxin controlled. Sequence Verified. Sf9/HEK293 expressed. |
View RAPSN Products |
| Gene Delivery | RAPSN Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and AChR clustering assays. |
View RAPSN Products |
| Benchmark Ab | Anti-RAPSN Recombinant Antibody High-affinity positive control for Western Blot, ICC, and IP. |
View RAPSN Products |
| Validator | RAPSN siRNA Set Target-specific knockdown verification in C2C12 or human muscle cell lines. |
View RAPSN Products |
| Related Target A | CHRNA1 (AChR Alpha-1 Subunit) Primary interaction partner of RAPSN at the postsynaptic membrane. |
View CHRNA1 Products |
| Related Target B | MUSK (Muscle-Specific Kinase) Key upstream kinase driving RAPSN-mediated acetylcholine receptor clustering. |
View MUSK Products |
| Related Target C | LRP4 (LDL Receptor-Related Protein 4) Agrin receptor forming the LRP4-MuSK complex to initiate RAPSN activation. |
View LRP4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| AChR Clustering Recapitulation | Sequence-verified RAPSN Lentivirus ensures stable, high-level expression in C2C12 myotubes. |
| CMS Mutation Modeling (e.g., N88K) | Recombinant RAPSN Mutant Proteins precisely engineered to study binding affinity disruption. |
| Lack of Controls | Recombinant positive control antibodies and validated siRNA sets included for assay normalization. |
| High Background in Binding Assays | Sf9/HEK293 eukaryotic expression systems preserve native-like post-translational modifications. |
Live RAPSN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of RAPSN (Receptor-Associated Protein of the Synapse) is an emerging frontier in neuromuscular medicine. RAPSN acts as an essential intracellular scaffolding protein and an E3 ubiquitin ligase, orchestrating the clustering of nicotinic acetylcholine receptors (AChRs) at the neuromuscular junction (NMJ). Loss-of-function mutations in RAPSN, most notably the N88K missense mutation, are a primary cause of postsynaptic Congenital Myasthenic Syndrome (CMS type 11).
While traditional neuromuscular therapies have focused on symptomatic relief (such as acetylcholinesterase inhibitors) or broad immunosuppression, modern drug discovery is shifting toward genetic correction, mRNA therapeutics, and small-molecule chaperones. The next wave of R&D targets the stabilization of the RAPSN-AChR interaction and the prevention of premature RAPSN degradation via its E3 ligase pathway, offering disease-modifying potential for CMS and sarcopenia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Academic Medical Centers, Biotech Startups | Congenital Myasthenic Syndrome (CMS) | Expression validation (Need Lentiviral positive controls & sequence-verified ORFs) |
| Small Molecule Chaperones | Neuromuscular Specialty Pharma | Muscle Atrophy, Myasthenia Gravis | Binding affinity assays (Need high-purity WT vs Mutant RAPSN proteins) |
| mRNA Therapeutics | RNA-focused Biotechs | Postsynaptic NMJ Defects | Functional clustering assays in vitro (Need validated siRNA for knock-down/knock-in rescue) |